The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis

20002,521 citationsJournal Articlebronze Open Access

Authors

Gideon Steinbach · The University of Texas MD Anderson Cancer Center

Patrick M. Lynch · The University of Texas MD Anderson Cancer Center

Robin Phillips · St. Mark's Hospital

Marina Wallace · St. Mark's Hospital

Ernest T. Hawk · National Cancer Institute

Gary Gordon

Naoki Wakabayashi · The University of Texas MD Anderson Cancer Center

Abstract

In patients with familial adenomatous polyposis, six months of twice-daily treatment with 400 mg of celecoxib, a cyclooxygenase-2 inhibitor, leads to a significant reduction in the number of colorectal polyps.

Topics & Keywords

Inflammatory mediators and NSAID effects Genetic factors in colorectal cancer Helicobacter pylori-related gastroenterology studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 342, Issue 26, pp. 1946-1952

DOI: 10.1056/nejm200006293422603

Field-Weighted Citation Impact: 144.18